About > Company
The Adial Vision
To build the world’s leading pharmaceutical company focused on improving the quality of life of patients by preventing and treating addiction and other unmet medical needs.
Adial is at an important inflection point with our many recent accomplishments. Addiction is a devastating disease that takes an enormous toll on our families, communities, country and the economy. I am excited to lead Adial as we advance our mission to bring life-transforming therapies to patients who are in need. This begins with our lead investigational drug candidate, AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder and other addictions.
Cary J. Claiborne Chief Executive Officer
The Adial Story
Adial History
Adial Pharmaceuticals was founded in 2010, following pioneering research into the genetics of addiction that began in the 1990s. The research focused on the potential of a serotonin-3 blocker to aid individuals with certain genetic markers related to the serotonin system. This hypothesis was tested through animal studies, imaging studies, and early clinical work, culminating in a Phase 2 study conducted by the University of Virginia at multiple sites. The successful outcomes of these studies led to the formation of Adial.
Adial Timeline
-
2010–2011
Adial Founded
Licenses AD04 from the University of Virginia
-
2014
USPTO grants 1st U.S. patent for AD04 for the treatment of Alcohol Use Disorder (AUD) in genetically targeted patients
-
2018
Adial Pharmaceuticals listed on U.S. NASDAQ
(Ticker: ADIL)
-
2020
ONWARD Phase 3
ADO4 Onward Phase 3 Trials begin
-
2022
ONWARD Phase 3 Trials completed
ONWARD Phase 3 Trial results announced